What is the drug of choice for acute epididymo‑orchitis?

Drug of Choice for Acute Epididymo-Orchitis

The drug of choice depends on the suspected pathogen based on patient age and risk factors: for sexually active men under 35 with STI risk, use ceftriaxone 1 g IM/IV plus doxycycline 100 mg twice daily for 10–14 days; for men over 35 or those with enteric pathogen risk, use ofloxacin 300 mg twice daily or levofloxacin 500 mg once daily for 10–14 days. 12

Treatment Algorithm Based on Risk Stratification

For Sexually Transmitted Pathogens (Age 14–35, Sexually Active)

• First-line regimen: Ceftriaxone 1 g intramuscularly or intravenously as a single dose PLUS doxycycline 100 mg orally twice daily for 10–14 days 3124
• This combination covers both Neisseria gonorrhoeae (including strains with reduced susceptibility) and Chlamydia trachomatis, the most common pathogens in this age group 45
• Alternative when ceftriaxone unavailable: Cefixime 400 mg orally single dose plus azithromycin 1 g orally single dose, followed by completion of doxycycline therapy 1

For Enteric Organisms (Age >35, Urinary Tract Risk Factors)

• First-line monotherapy: Ofloxacin 300 mg orally twice daily for 10–14 days OR levofloxacin 500 mg orally once daily for 10–14 days 3145
• These fluoroquinolones achieve excellent tissue penetration into the epididymis and testis 1
• Enteric organisms (primarily E. coli and other Enterobacterales) are the predominant pathogens in men with bladder outlet obstruction, benign prostatic hyperplasia, or recent urinary instrumentation 356

For Mixed Risk (STI + Enteric Pathogen Risk)

• Combination therapy: Ceftriaxone 1 g IM/IV single dose PLUS either ofloxacin 300 mg twice daily or levofloxacin 500 mg once daily for 10–14 days 24
• This applies to men who practice insertive anal intercourse or have both sexual and urinary tract risk factors 145

Specific Pathogen-Directed Therapy

Non-Gonococcal Infection (Unidentified Pathogen)

• Doxycycline 100 mg twice daily for 7 days as first-line 3
• Alternative: Azithromycin 500 mg on day 1, then 250 mg for 4 days 3

Chlamydia trachomatis

• Azithromycin 1.0–1.5 g orally single dose OR doxycycline 100 mg twice daily for 7 days 3
• Alternative: Levofloxacin 500 mg once daily for 7 days or ofloxacin 200 mg twice daily for 7 days 3

Mycoplasma genitalium

• Azithromycin 500 mg on day 1, then 250 mg for 4 days 3
• For macrolide-resistant strains: Moxifloxacin 400 mg once daily for 7–14 days 314

Critical Diagnostic Steps to Guide Therapy

• Gram stain of urethral discharge to detect gram-negative intracellular diplococci indicating gonorrhea 14
• Nucleic acid amplification test (NAAT) on first-void urine or urethral swab for C. trachomatis and N. gonorrhoeae 1
• Urine culture and urinalysis to identify enteric bacterial pathogens and assess for leucocytes/nitrites 14
• Urethral swab culture for gonorrhea to determine antimicrobial resistance profiles 1

Common Pitfalls and How to Avoid Them

Do NOT Use Fluoroquinolones for STI-Related Cases

• Fluoroquinolones should never be used as first-line agents when gonorrhea is suspected due to widespread gonococcal resistance to this class 147
• Rising ciprofloxacin resistance in E. coli also limits fluoroquinolone utility even for enteric infections in some regions 6

Do NOT Delay Empiric Therapy

• Start treatment immediately based on clinical presentation and risk assessment while awaiting culture results 1
• Untreated acute epididymitis can lead to testicular loss (5% risk), abscess formation, infertility, and chronic scrotal pain 58

Do NOT Overlook Mycoplasma genitalium

• Consider M. genitalium in cases that persist after standard therapy, particularly in sexually active men 314
• Treat macrolide-resistant strains with moxifloxacin 400 mg daily for 7–14 days 31

Do NOT Use Dual Azithromycin Therapy Routinely

• The use of dual therapy with azithromycin alongside ceftriaxone is no longer recommended unless cefixime is being given as an alternative to ceftriaxone 2
• This represents a change from older guidelines 7

Adjunctive Management

• Supportive care including bed rest, scrotal elevation, and analgesics until fever and inflammation resolve 1
• Sexual partner evaluation and treatment when STI pathogens are suspected or confirmed 1
• Abstinence from sexual activity until both patient and partners complete therapy 1

Follow-Up Requirements

• Early reassessment within 3 days if no clinical improvement occurs; consider alternative diagnoses such as testicular torsion, tumor, or abscess 1
• Persistent swelling after completing antibiotics warrants comprehensive evaluation for abscess formation (which significantly correlates with need for orchidectomy), neoplasm, or atypical infections including tuberculosis 18
• Readmission rates for recurrent epididymo-orchitis approach 14%, necessitating investigation for underlying urological abnormalities 8